INmune Bio hits record low as Alzheimer's drug misses mid-stage trial goal
ReutersJun 30, 2025 1:53 PM
Shares of drug developer INmune Bio INMB.O fall as much as 61.53% to an all-time low of $2
*Stock set for its worst day ever, if losses hold
Co's experimental Alzheimer's drug, XPro, did not meet the main goal of improving cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage trial
XPro is designed to target and inhibit inflammatory signals associated with a type of protein called tumor necrosis factor without suppressing the immune system
Co plans to file for FDA breakthrough therapy designation and schedule an End-of-Phase 2 meeting with the health regulator in Q4 2025
Including session moves, stock down 53.3% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Should You Invest in the “Magnificent Seven” in 2026? One Stock or All of Them?
TradingKey - The Magnificent Seven defined markets in 2024 and remained at the heart of the 2025 story. Collectively, they have unparalleled control over AThe Magnificent Seven includes Nvidia (NVDA), Apple (AAPL), Alphabet (GOOG) (GOOGL), Microsoft (MSFT), Amazon (AMZN), Meta Platforms (META), andTradingKey
10 minutes ago
January CPI Revives Rate-Cut Hopes; Gold and Silver Rebound, But Is the Bull Run Intact?
TradingKey - During Friday's US session, spot gold surged back above $5,000 to close at $5,043, while silver resumed its rally, breaking through the $75 mark to peak near $79 before closing at $77.43. This movement was primarily driven by data from the U.S. Bureau of Labor Statistics that significanTradingKey
Sun, Feb 15
SpaceX IPO with Dual-Class Shares: Will Musk Secure the 25% Voting Control Denied by Tesla?
TradingKey - SpaceX is preparing for an IPO this year. According to foreign media reports, SpaceX is considering a dual-class share structure for its IPO, which would grant specific shareholders extra voting rights. In other words, Elon Musk could maintain absolute control over the company even if hTradingKey
Sat, Feb 14
Silver Plunges 10%, Gold Tests $4,900: Is the Bull Market Over Ahead of CPI?
TradingKey - Ahead of the release of the U.S. January CPI report, financial markets experienced a sudden broad sell-off on Thursday. Alongside a sharp decline in U.S. equities, prices for commodities such as gold (XAUUSD) also plummeted. Gold dropped nearly $200 within a 30-minute window, a declineTradingKey
Fri, Feb 13
